论文部分内容阅读
目的:分析研讨妇科恶性肿瘤放化疗、腹腔灌注化疗及恶性转移性腹水结合热疗在临床上的应用效果。方法:此研究中所讨论的48例患者均随机选取于2015年11月至2016年3月期间我院收治的妇科恶性肿瘤患者中,48例患者随机均分两组研讨,对照组(24例)接受腹腔灌注化疗,研究组(24例)接受腹腔灌注化疗和内生场热疗治疗转移性腹水状况,对比其治疗状况。结果:随访一年内,研究组生存率58.33%和对照组25%比较,前者明显要高出33.33%,组间数据有统计学意义(P<0.05)。研究组总不良反应发生率20.83%比对照组25%低,组间数据无统计学意义(P>0.05)。结论:临床在治疗妇科恶性肿瘤合并转移性腹水疾病时可将腹腔灌注化疗联合内生场热疗作为一种治疗方式进行选择,此方式对其生存时间有延长作用,且安全可靠。
Objective: To analyze and discuss the clinical application of radiotherapy and chemotherapy, intraperitoneal chemotherapy and malignant ascites combined with hyperthermia in gynecological malignant tumors. Methods: Forty-eight patients in this study were randomized to receive gynecologic malignancy in our hospital from November 2015 to March 2016. Forty-eight patients were randomly divided into two groups: control group (24 patients ) Received intraperitoneal chemotherapy, the study group (24 patients) received intraperitoneal hyperthermic chemotherapy and endogenous hyperthermia in the treatment of metastatic ascites, compared to its treatment status. Results: Within one year of follow-up, the study group survival rate was 58.33%, compared with 25% in the control group, the former was significantly higher than the 33.33%, the data between the two groups was statistically significant (P <0.05). The incidence of adverse reactions in the study group was 20.83%, which was lower than 25% in the control group. There was no significant difference between the two groups (P> 0.05). Conclusion: Intraperitoneal chemotherapy combined with endogenous hyperthermia can be selected as a treatment modality in the treatment of gynecologic malignancies with metastatic ascites. This method can prolong the survival time and be safe and reliable.